GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research PLC is advancing its clinical candidate GH001 through promising Phase IIb trial results, achieving a significant -15.5 placebo-adjusted improvement on the MADRS scale at Day 8, indicating strong antidepressant efficacy. The company's focus on novel mebufotenin therapies positions it favorably within a regulatory environment that is increasingly supportive of psychedelic treatments, potentially enhancing market opportunities in Europe and across other indications such as postpartum and bipolar depression. Positive data in concurrent studies underline the prospect of durable clinical improvements, contributing to a favorable long-term outlook for GH Research's financial performance and growth potential.
Bears say
GH Research PLC faces significant risks that contribute to a negative outlook on its stock, primarily due to the potential for unexpected safety events or efficacy challenges associated with its mebufotenin therapies. Limitations in clinical trial progress stemming from regulatory hurdles or requirements could lead to delays or even a halt in development, impacting the company's ability to successfully bring products to market and generate revenue. Furthermore, fluctuations in remission rates observed in studies raise concerns over the long-term effectiveness of its treatments, highlighting the uncertainty surrounding the company's future performance and profitability.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares